Adaptive Biotechnologies (ADPT) Other Operating Expenses (2018 - 2026)

Adaptive Biotechnologies has disclosed Other Operating Expenses across 9 years of filings, most recently posting $44.8 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $44.8 million, up 10.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.0 million (up 4.61% YoY), and the FY2025 annual result was $167.6 million, up 2.37% from the prior year.
• Other Operating Expenses came in at $44.8 million for Q1 2026 at Adaptive Biotechnologies, up from $43.1 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $67.4 million in Q4 2023 to a low of $36.8 million in Q3 2022.
• The 5-year median for Other Operating Expenses is $40.7 million (2022), against an average of $42.5 million.
• Across the five-year window, Other Operating Expenses jumped 65.41% in 2023 and sank 40.69% in 2024, its largest moves.
• Adaptive Biotechnologies' Other Operating Expenses stood at $40.7 million in 2022, then jumped by 65.41% to $67.4 million in 2023, then tumbled by 40.69% to $40.0 million in 2024, then rose by 7.94% to $43.1 million in 2025, then climbed by 3.93% to $44.8 million in 2026.
• The last three Other Operating Expenses figures came in at $44.8 million (Q1 2026), $43.1 million (Q4 2025), and $42.1 million (Q3 2025), per Business Quant data.